Literature DB >> 27867624

Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approaches.

Valentina Mazza1, Federico Cappuzzo1.   

Abstract

Entities:  

Year:  2016        PMID： 27867624      PMCID： PMC5107516          DOI： 10.21037/jtd.2016.10.99

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  15 in total

Review 1.  Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Authors:  Floris Dammeijer; Lysanne A Lievense; G D Marijn Veerman; Henk C Hoogsteden; Joost P Hegmans; Lidia R Arends; Joachim G Aerts
Journal:  J Clin Oncol       Date:  2016-07-18       Impact factor: 44.544

Review 2.  Immunotherapy for lung cancer: advances and prospects.

Authors:  Li Yang; Liping Wang; Yi Zhang
Journal:  Am J Clin Exp Immunol       Date:  2016-03-23

Review 3.  Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.

Authors:  Scott J Antonia; Johan F Vansteenkiste; Edmund Moon
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

4.  Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Authors:  Charles Butts; Mark A Socinski; Paul L Mitchell; Nick Thatcher; Libor Havel; Maciej Krzakowski; Sergiusz Nawrocki; Tudor-Eliade Ciuleanu; Lionel Bosquée; José Manuel Trigo; Alexander Spira; Lise Tremblay; Jan Nyman; Rodryg Ramlau; Gun Wickart-Johansson; Peter Ellis; Oleg Gladkov; José Rodrigues Pereira; Wilfried Ernst Erich Eberhardt; Christoph Helwig; Andreas Schröder; Frances A Shepherd
Journal:  Lancet Oncol       Date:  2013-12-09       Impact factor: 41.316

5.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

6.  A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.

Authors:  G Giaccone; L A Bazhenova; J Nemunaitis; M Tan; E Juhász; R Ramlau; M M van den Heuvel; R Lal; G H Kloecker; K D Eaton; Q Chu; D J Dunlop; M Jain; E B Garon; C S Davis; E Carrier; S C Moses; D L Shawler; H Fakhrai
Journal:  Eur J Cancer       Date:  2015-08-14       Impact factor: 9.162

7.  Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Johan F Vansteenkiste; Byoung Chul Cho; Tonu Vanakesa; Tommaso De Pas; Marcin Zielinski; Moon Soo Kim; Jacek Jassem; Masahiro Yoshimura; Jubrail Dahabreh; Haruhiku Nakayama; Libor Havel; Haruhiko Kondo; Tetsuya Mitsudomi; Konstantinos Zarogoulidis; Oleg A Gladkov; Katalin Udud; Hirohito Tada; Hans Hoffman; Anders Bugge; Paul Taylor; Emilio Esteban Gonzalez; Mei Lin Liao; Jianxing He; Jean-Louis Pujol; Jamila Louahed; Muriel Debois; Vincent Brichard; Channa Debruyne; Patrick Therasse; Nasser Altorki
Journal:  Lancet Oncol       Date:  2016-04-27       Impact factor: 41.316

8.  Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

Authors:  U Gatzemeier; G Groth; C Butts; N Van Zandwijk; F Shepherd; A Ardizzoni; C Barton; P Ghahramani; V Hirsh
Journal:  Ann Oncol       Date:  2004-01       Impact factor: 32.976

9.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

10.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

Authors:  Robert Pirker; Jose R Pereira; Aleksandra Szczesna; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Ihor Vynnychenko; Keunchil Park; Chih-Teng Yu; Valentyn Ganul; Jae-Kyung Roh; Emilio Bajetta; Kenneth O'Byrne; Filippo de Marinis; Wilfried Eberhardt; Thomas Goddemeier; Michael Emig; Ulrich Gatzemeier
Journal:  Lancet       Date:  2009-05-02       Impact factor: 79.321
View more
  2 in total

1.  CpG-ODN Facilitates Effective Intratracheal Immunization and Recall of Memory against Neoantigen-Expressing Alveolar Cells.

Authors:  Mathias Riehn; Marcin Cebula; Hansjörg Hauser; Dagmar Wirth
Journal:  Front Immunol       Date:  2017-09-29       Impact factor: 7.561

2.  The Role of Upregulated DDX11 as A Potential Prognostic and Diagnostic Biomarker in Lung Adenocarcinoma.

Authors:  Jianhao Li; Liwen Liu; Xin Liu; Penglin Xu; Qiuyue Hu; Yan Yu
Journal:  J Cancer       Date:  2019-07-10       Impact factor: 4.207
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.